Related Experiment Video
Updated: Jul 8, 2026
08:56
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Aspirin and gastrointestinal toxicity.
1Department of Gastroenterology, Ibni-Sina Hospital, Ankara University Medical School, Sihhiye, Ankara, Turkey. murattoruner@yahoo.com
Summary
Aspirin is crucial for cardiovascular disease prevention but carries gastrointestinal risks. For high-risk patients, Helicobacter pylori eradication and proton pump inhibitors can mitigate these aspirin-related side effects.
Area of Science:
- Cardiology
- Gastroenterology
- Pharmacology
Background:
- Aspirin is a cornerstone in cardiovascular disease prevention.
- Gastrointestinal toxicity, including ulcers and bleeding, is a significant side effect of aspirin therapy.
- Both conventional and enteric-coated aspirin share similar gastrointestinal toxicity profiles.
Purpose of the Study:
- To evaluate the risks and management strategies for aspirin-induced gastrointestinal toxicity.
- To identify protective measures for patients with cardiovascular disease at high risk for gastrointestinal bleeding.
Main Methods:
- Review of existing literature on aspirin's gastrointestinal effects.
- Analysis of risk factors for gastrointestinal bleeding in aspirin users.
- Evaluation of prophylactic strategies, including Helicobacter pylori eradication and proton pump inhibitor use.
Main Results:
- Even low-dose aspirin can cause gastrointestinal bleeding.
- No significant difference in gastrointestinal toxicity between conventional and enteric-coated aspirin.
- Helicobacter pylori eradication and proton pump inhibitor therapy show potential in reducing gastrointestinal toxicity.
Conclusions:
- Cardiovascular patients on aspirin require careful monitoring for gastrointestinal side effects.
- Prophylactic strategies are recommended for high-risk individuals to minimize aspirin-related gastrointestinal complications.
Related Concept Videos
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
01:30Other Disorders of Digestive System
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:17Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...